SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MEDX ... anybody following?
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2240 62 0 MEDX
Emcee:  Ed Offstein Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2115Invariant natural killer T cells regulate breast cancer response to radiation anIcebrg-1/17/2009
2114Potentiating Endogenous Antitumor Immunity to Prostate Cancer through CombinatioIcebrg-1/15/2009
2113Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma. J Clin OIcebrg-1/15/2009
2112Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patieIcebrg11/15/2009
2111More like a pienny :)rkrw-1/13/2009
2110Just a hint to analysts to revise their models and raise their targets by a bucktuck-1/13/2009
2109Celldex Announces Sale of Poultry Vaccines Business to Lohmann NEEDHAM, Mass.--Icebrg-1/13/2009
2108The first time I read it quickly I thought $12.2M burn per quarter, good work. rkrw-1/13/2009
2107Somebody must have made a typo. ;-) Medarex expects a cash burn rate per monthLJM-1/13/2009
2106Medarex puts out a PR to announce their burn rate is being cut ***$200,000*** perkrw-1/13/2009
2105Merck PD-1 Paper Published A new study of PD-1 blockade, conducted by researcheIcebrg-1/7/2009
2104PD-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic VIcebrg-1/7/2009
2103Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its ManIcebrg-12/25/2008
2102Enhancing SIV-specific immunity in vivo by PD-1 blockade. Velu V, Titanji K, ZhIcebrg-12/22/2008
2101Disregard my prior post as I see the discussion from before regarding the royaltmcbio-12/22/2008
2100Is it known what the royalty rate will be? Mid-single digits?mcbio-12/22/2008
2099Compare that to MCF: Message 25267188The Dodgy Ticker-12/19/2008
2098Celldex Therapeutics downgraded to Hold at Needham. Needham downgrades CLDX to Icebrg-12/19/2008
2097FDA Issues Complete Response Letter To Centocor for Ustekinumab Biologic LicenseIcebrg-12/19/2008
2096Pfizer and Celldex Therapeutics Announce Amendment to ACT III Study of CDX-110 iIcebrg-12/19/2008
2095FibroGen Has Commenced an Open-Label, Phase 1 Clinical Trial of FG-3019, Anti-CoIcebrg-12/16/2008
2094A small molecule CXCR4 antagonist approved: Message 25254958nigel bates-12/15/2008
2093Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) fIcebrg-12/15/2008
2092Approval of STELARA(TM) in Canada Marks Advancement in Treatment of Moderate to Icebrg-12/15/2008
2091CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in meIcebrg-12/12/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News